The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

Beginning in the late 1970s, he effectively became a master builder in the nano universe — seeking how to use molecular bonds to fashion biological structures designed with a special purpose.

but that it is a chemical evolution of millions of years, absolutely random, like subsequent biological evolution, and that it increases in complexity over time. It can lead to self-organized ...

Cavendish Laboratory, Department of Physics, University of Cambridge, J. J. Thomson Avenue, Cambridge CB3 0HE, U.K. ISIS Neutron and Muon Source, STFC Rutherford Appleton Laboratory, Harwell Science ...

A new study suggests that Stonehenge was built to unite the ancient Britons. This grand monument may have served as a symbol of unity when new groups from Europe were arriving in the region.

“Recently, we added defactinib to the combination of avutometinib and sotorasib in our RAMP 203 trial. Preliminary data for the triplet combination have shown a generally favorable tolerability ...

Verastem (VSTM) announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small ...

No dose-limiting toxicities were observed in the RAMP 203 first triplet combination cohort of avutometinib and LUMAKRAS™ (sotorasib) plus defactinib in patients previously treated with a G12C ...